SEC Comment Letter for Q32 Bio Inc. (QTTB) (CIK 0001661998) (QTTB) — Feb 12, 2018
Q32 Bio Inc. (QTTB) (CIK 0001661998)
Date: Feb. 12, 2018 · CIK: 0001661998 · Accession: 0000000000-18-004746
AI Filing Summary & Sentiment
Reasoning
Letter
February 9, 2018 Arthur Tzianabos President and Chief Executive Officer Homology Medicines, Inc. 45 Wiggins Avenue Bedford, MA 01730 Re:Homology Medicines, Inc. Amendment No. 1 to Draft Registration Statement on Form S-1 Submitted January 30, 2018 CIK 0001661998 Dear Dr. Tzianabos: We have reviewed your amended registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure. Please respond to this letter by amending your registration statement and providing the requested information. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response. After reviewing any amendment to your registration statement and the information you provide in response to these comments, we may have additional comments. Unless we note otherwise, our references to prior comments are to comments in our January 19, 2018 letter. DRS on Form S-1 Submitted January 30, 2018 Prospectus Summary, page 1 1.We note your response to comment 1. Please balance your disclosure in the Summary by clearly stating that you are a preclinical company, you have not submitted an IND for HMI-102 or any other product candidate, and that you will require additional capital to move beyond Phase 1/2.
FirstName LastNameArthur Tzianabos Comapany NameHomology Medicines, Inc. June 16, 2017 Page 2 FirstName LastName Arthur Tzianabos Homology Medicines, Inc. February 9, 2018 Page 2
You may contact Keira Nakada at 202-551-3659 or Angela Connell at 202-551-3426 if you have questions regarding comments on the financial statements and related matters. Please contact Jeff Gabor at 202-551-2544 or Erin Jaskot at 202-551-3442 with any other questions. Division of Corporation Finance Office of Healthcare & Insurance cc: Wesley Holmes
Show Raw Text
February 9, 2018
Arthur Tzianabos
President and Chief Executive Officer
Homology Medicines, Inc.
45 Wiggins Avenue
Bedford, MA 01730
Re:Homology Medicines, Inc.
Amendment No. 1 to Draft Registration Statement on Form S-1
Submitted January 30, 2018
CIK 0001661998
Dear Dr. Tzianabos:
We have reviewed your amended registration statement and have the following
comments. In some of our comments, we may ask you to provide us with information so we
may better understand your disclosure.
Please respond to this letter by amending your registration statement and providing the
requested information. If you do not believe our comments apply to your facts and
circumstances or do not believe an amendment is appropriate, please tell us why in your
response.
After reviewing any amendment to your registration statement and the information you
provide in response to these comments, we may have additional comments. Unless we note
otherwise, our references to prior comments are to comments in our January 19, 2018 letter.
DRS on Form S-1 Submitted January 30, 2018
Prospectus Summary, page 1
1.We note your response to comment 1. Please balance your disclosure in the Summary by
clearly stating that you are a preclinical company, you have not submitted an IND for
HMI-102 or any other product candidate, and that you will require additional capital to
move beyond Phase 1/2.
FirstName LastNameArthur Tzianabos
Comapany NameHomology Medicines, Inc.
June 16, 2017 Page 2
FirstName LastName
Arthur Tzianabos
Homology Medicines, Inc.
February 9, 2018
Page 2
You may contact Keira Nakada at 202-551-3659 or Angela Connell at 202-551-3426 if
you have questions regarding comments on the financial statements and related matters. Please
contact Jeff Gabor at 202-551-2544 or Erin Jaskot at 202-551-3442 with any other questions.
Division of Corporation Finance
Office of Healthcare & Insurance
cc: Wesley Holmes